Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Community Practice Connections™: Navigating a New Era of Food Allergy Management
View More
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arizona
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Nevada
View More
Eye Care Symposia in Los Angeles
April 25-26, 2025
Register Now!
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Missouri
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | New Mexico
View More
Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 66th ASH Annual Meeting
April 26-27, 2025
Register Now!
Nationwide Avian Flu Response Gains Momentum, Yet Urgent Action Remains Essential
The ongoing H5N1 avian flu outbreak has severely impacted U.S. poultry and dairy industries, prompting a $1 billion USDA response strategy that includes biosecurity, vaccination research, and innovation funding. With growing concern over viral mutations affecting humans and livestock, rapid, field-based diagnostic tools offer critical support in accelerating detection and containment efforts.
MAD-ID 2025 Highlights Fidaxomicin’s Role in Reducing C difficile Recurrence
Multiple studies highlight fidaxomicin’s effectiveness across high-risk populations despite cost and access challenges, underscoring the need for education and stewardship to improve guideline adherence.
Top 5 Infectious Disease News stories Week of May 31-June 7
June 7th 2025This week, FDA approved Moderna’s improved COVID-19 vaccine mRNA, MAD-ID findings showed omadacycline’s 86% success rate in treating infections in immunocompromised patients, consistent safety in preventing recurrent CDI in patients with comorbidities, and more.
Gyre Therapeutics' Hydronidone Meets Primary Endpoint in Phase 3 Hepatitis B Trial
June 4th 2025Hydronidone demonstrated significant efficacy in liver fibrosis regression in CHB patients, meeting the primary endpoint in a phase 3 trial. The company plans to file regulatory applications in China and the US, aiming to expand the therapy's indications.